Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET-1 Study)
Sponsor: Oyster Point Pharma, Inc.
A PHASE2 clinical study on Dry Eye Disease, this trial is completed. The trial is conducted by Oyster Point Pharma, Inc. and has accumulated 12 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Nov 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Feb 2021 — Nov 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Completed PHASE2
-
Nov 2018 — Apr 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oyster Point Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .